Our findings demonstrate that multiple prostate-cancer antigen-expressing aAVCs can promote tumor epitope spreading as well as activate multiple antigen-specific CD8+ T cells, representing a promising therapeutic option for conventional therapy-resistant prostate cancer. Here, CD8A is linked to prostate carcinoma.